Regeneron Pharmaceuticals, Inc. (REGN) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $614.32 (-0.08%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 9, 2026 | Greg Renza | Truist Financial | $818.00 | +33.2% |
| Mar 6, 2026 | Eliana Merle | Barclays | $923.00 | +50.2% |
| Mar 2, 2026 | Brian Abrahams | RBC Capital | $765.00 | +24.5% |
| Feb 2, 2026 | Carter Gould | Cantor Fitzgerald | $800.00 | +30.2% |
| Feb 2, 2026 | Brian Skorney | Robert W. Baird | $742.00 | +20.8% |
| Feb 2, 2026 | William Pickering | Tudor Pickering | $925.00 | +50.6% |
| Feb 1, 2026 | Terence Flynn | Morgan Stanley | $769.00 | +25.2% |
| Jan 27, 2026 | William Pickering | Tudor Pickering | $916.00 | +49.1% |
| Jan 27, 2026 | Brian Abrahams | RBC Capital | $745.00 | +21.3% |
| Dec 17, 2025 | Andrew Berens | Leerink Partners | $873.00 | +42.1% |
| Dec 12, 2025 | Terence Flynn | Morgan Stanley | $768.00 | +25.0% |
| Dec 4, 2025 | Evan Seigerman | BMO Capital | $850.00 | +38.4% |
| Nov 20, 2025 | Mohit Bansal | Wells Fargo | $700.00 | +13.9% |
| Oct 29, 2025 | Carter Gould | Cantor Fitzgerald | $740.00 | +20.5% |
| Oct 29, 2025 | Evan Seigerman | BMO Capital | $725.00 | +18.0% |
| Oct 29, 2025 | Brian Skorney | Robert W. Baird | $630.00 | +2.6% |
| Oct 28, 2025 | Christopher Raymond | Raymond James | $723.00 | +17.7% |
| Sep 2, 2025 | Christopher Raymond | Raymond James | $673.00 | +9.6% |
| Aug 1, 2025 | Mohit Bansal | Wells Fargo | $580.00 | -5.6% |
| Aug 1, 2025 | Geoff Meacham | Citigroup | $650.00 | +5.8% |
Top Analysts Covering REGN
REGN vs Sector & Market
| Metric | REGN | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.33 | 2.24 | 2.40 |
| Analyst Count | 30 | 8 | 19 |
| Target Upside | +36.1% | +11475.0% | +17.1% |
| P/E Ratio | 14.97 | 3.90 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $3.63B | $3.80B | $4.00B | 13 |
| 2026-09-30 | $3.93B | $4.15B | $4.39B | 6 |
| 2026-12-31 | $4.11B | $4.34B | $4.59B | 6 |
| 2027-03-31 | $3.98B | $4.20B | $4.45B | 6 |
| 2027-06-30 | $4.20B | $4.44B | $4.70B | 6 |
| 2027-09-30 | $4.36B | $4.60B | $4.87B | 6 |
| 2027-12-31 | $4.55B | $4.81B | $5.09B | 6 |
| 2028-12-31 | $18.76B | $18.76B | $18.77B | 22 |
| 2029-12-31 | $18.58B | $20.31B | $22.19B | 15 |
| 2030-12-31 | $19.62B | $21.44B | $23.43B | 11 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $7.56 | $10.58 | $11.82 | 13 |
| 2026-09-30 | $11.80 | $12.67 | $13.63 | 5 |
| 2026-12-31 | $12.27 | $13.18 | $14.18 | 5 |
| 2027-03-31 | $11.49 | $12.34 | $13.27 | 5 |
| 2027-06-30 | $12.80 | $13.75 | $14.79 | 5 |
| 2027-09-30 | $13.25 | $14.23 | $15.31 | 5 |
| 2027-12-31 | $14.01 | $15.05 | $16.19 | 5 |
| 2028-12-31 | $49.15 | $60.49 | $74.23 | 8 |
| 2029-12-31 | $60.00 | $67.46 | $75.58 | 6 |
| 2030-12-31 | $64.16 | $72.14 | $80.83 | 6 |
Frequently Asked Questions
What is the analyst consensus for REGN?
The consensus among 30 analysts covering Regeneron Pharmaceuticals, Inc. (REGN) is Buy with an average price target of $862.74.
What is the highest price target for REGN?
The highest price target for REGN is $1300.00, set by Evan David Seigerman at BMO Capital on 2024-09-12.
What is the lowest price target for REGN?
The lowest price target for REGN is $580.00, set by Mohit Bansal at Wells Fargo on 2025-08-01.
How many analysts cover REGN?
30 analysts have issued ratings for Regeneron Pharmaceuticals, Inc. in the past 12 months.
Is REGN a buy or sell right now?
Based on 30 analyst ratings, REGN has a consensus rating of Buy (2.33/5) with a +36.1% upside to the consensus target of $862.74.
What are the earnings estimates for REGN?
Analysts estimate REGN will report EPS of $10.58 for the period ending 2026-06-30, with revenue estimated at $3.80B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.